Ponesimod用于治疗复发缓解型多发性硬化症

IF 1.3 Q4 NEUROSCIENCES

Progress in Neurology and Psychiatry Pub Date : 2022-04-01 DOI:10.1002/pnp.745

T. Gaber, M. Eltemamy

{"title":"Ponesimod用于治疗复发缓解型多发性硬化症","authors":"T. Gaber, M. Eltemamy","doi":"10.1002/pnp.745","DOIUrl":null,"url":null,"abstract":"Gone are the days when neurologists considering disease modifying therapy for their patients with relapsing remitting multiple sclerosis (RRMS) could only access a handful of agents that are easy to compare. This charmingly simple situation has rapidly evolved to an increased ability to access a variety of agents that are potentially suitable for the equally complex spectrum of RRMS syndromes with different clinical and radiological features. The approval of ponesimod by NICE as a first‐ or second‐line treatment for RRMS is another welcomed addition to the current agents available.","PeriodicalId":43913,"journal":{"name":"Progress in Neurology and Psychiatry","volume":null,"pages":null},"PeriodicalIF":1.3000,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Ponesimod for the treatment of relapsing‐remitting multiple sclerosis\",\"authors\":\"T. Gaber, M. Eltemamy\",\"doi\":\"10.1002/pnp.745\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Gone are the days when neurologists considering disease modifying therapy for their patients with relapsing remitting multiple sclerosis (RRMS) could only access a handful of agents that are easy to compare. This charmingly simple situation has rapidly evolved to an increased ability to access a variety of agents that are potentially suitable for the equally complex spectrum of RRMS syndromes with different clinical and radiological features. The approval of ponesimod by NICE as a first‐ or second‐line treatment for RRMS is another welcomed addition to the current agents available.\",\"PeriodicalId\":43913,\"journal\":{\"name\":\"Progress in Neurology and Psychiatry\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2022-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Progress in Neurology and Psychiatry\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/pnp.745\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"NEUROSCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Progress in Neurology and Psychiatry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/pnp.745","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 0

摘要

考虑为复发缓解型多发性硬化症（RRMS）患者进行疾病改良治疗的神经学家只能获得少数易于比较的药物的日子已经一去不复返了。这种迷人的简单情况已经迅速发展为获得各种药物的能力增强，这些药物可能适用于具有不同临床和放射学特征的同样复杂的RRMS综合征。NICE批准波奈西莫德作为RRMS的一线或二线治疗是目前可用药物的又一个受欢迎的补充。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Ponesimod for the treatment of relapsing‐remitting multiple sclerosis

Gone are the days when neurologists considering disease modifying therapy for their patients with relapsing remitting multiple sclerosis (RRMS) could only access a handful of agents that are easy to compare. This charmingly simple situation has rapidly evolved to an increased ability to access a variety of agents that are potentially suitable for the equally complex spectrum of RRMS syndromes with different clinical and radiological features. The approval of ponesimod by NICE as a first‐ or second‐line treatment for RRMS is another welcomed addition to the current agents available.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Progress in Neurology and Psychiatry NEUROSCIENCES-

CiteScore

1.70

自引率

8.30%

发文量

期刊介绍： Progress in Neurology and Psychiatry is published nine times a year, and is a journal for specialists in secondary care, GPs with an interest in neurology and psychiatry, community psychiatric nurses and other specialist healthcare professionals. Articles cover management, news updates and opinion in all areas of neurology and psychiatry.